IL-ISACA
26.1.2021 17:18:12 CET | Business Wire | Press release
As Data Privacy Day approaches this week, ISACA has released a new survey report, Privacy in Practice 2021: Data Privacy Trends, Forecasts and Challenges , exploring past and future trends in privacy by design, privacy obstacles and privacy workforce.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005846/en/
Privacy by Design
Enterprises that report they always use privacy by design are more likely to be driven by a combination of compliance and ethics (62 percent vs. 52 percent total). They are also nearly two-and-a-half times more likely to be completely confident in their privacy team’s ability to ensure data privacy and achieve compliance with new privacy laws and regulations (24 percent vs. 10 percent total). However, there was not a meaningful difference in the number of privacy breaches they experienced in the last 12 months compared to all respondents. Approximately 10 percent of both groups reported breaches—a potentially underreported number.
Privacy Obstacles
Respondents identified other common privacy failures, including:
- Lack of training or poor training (64 percent)
- Failure to perform a risk analysis (53 percent)
- Bad or nonexistent detection of personal information (50 percent)
Respondents cited privacy principles frameworks, experience-based credentials and privacy training as the most helpful methods in overcoming these obstacles.
Workforce Trends
Respondents indicated that they foresee an increased demand for technical privacy roles compared to legal/compliance roles (70 percent increase vs. 59 percent increase). However, technical privacy roles were more likely to be considered understaffed (46 percent vs. 33 percent).
Nevertheless, hiring managers have been filling these roles through training—47 percent noted they have been training non-privacy staff interested in moving into privacy roles. Ninety-two percent of respondents indicated that they have privacy staff who started their career in IT or security and moved into privacy and compliance.
“Organizations will continue needing a strong privacy workforce in the years ahead,” says Nader Qaimari, ISACA chief product officer. “As non-privacy professionals increasingly get opportunities to train for this career path and gain technical skills, it not only eases the privacy skills gap but enriches this workforce.”
The complimentary webinar, “Exploring Privacy Trends, Challenges & Predictions,” on 28 January 2021 at 12:00 PM EST / 5:00 PM (UTC) will explore the survey highlights. To learn more, visit www.isaca.org/education/online-events/lms_w012821 .
Access the Privacy in Practice 2021 survey report at www.isaca.org/privacy-in-practice-2021 . Learn more about ISACA’s privacy resources, including the Certified Data Privacy Solutions Engineer™ (CDPSE™) certification, at www.isaca.org/cdpse .
About ISACA
For more than 50 years, ISACA® (www.isaca.org ) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. Its presence in 188 countries includes more than 220 chapters.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005846/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
